What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The NEXUS study showed disease arrest in 7/20 evaluable patients, with 6/9 in the Gd-negative subgroup. However, the study was uncontrolled, and no direct comparative data versus standard of care (SOC) or competitors like HSCT or Skysona are available. The evidence is limited by the small sample size and lack of randomization.
Does the economic case hold at the expected price? — Cost effectiveness
No economic model, ICER, or cost-utility analysis was identified for leriglitazone. The absence of economic data precludes assessment of cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
No Nezglyal-specific pediatric HRQoL data are available. The NEXUS study did not report validated HRQoL instruments, and adult data from ADVANCE are not applicable to pediatric cALD.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Short-term safety data from NEXUS indicate manageable adverse events, with no severe or life-threatening events reported. However, long-term safety data are limited, and unresolved risks such as fluid retention and carcinogenicity require further surveillance.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal NEXUS study used a natural-history benchmark rather than active SOC comparators like HSCT or Skysona. This limits the relevance of the comparator for reimbursement purposes.
Is the population defined the way payers need it? — Patient Population and Subgroups
The NEXUS study population is representative of the narrow EU label for Gd-negative boys aged 2–12 years. However, the small sample size and lack of broader subgroup analyses limit generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nezglyal fits into the care pathway for early Gd-negative cALD, requiring MRI surveillance and transplant readiness. However, it necessitates specialist monitoring and infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource-use data are available for leriglitazone, preventing assessment of resource implications.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The NEXUS study was open-label and uncontrolled, with a small sample size. The reliance on a historical benchmark and lack of randomization limit the robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty remains due to the lack of randomization and reliance on historical benchmarks. Sensitivity analyses were performed, but broader impacts and economic sensitivity are not assessable.
